Evidence map›Paper›PMID 42832083›Full record

Observational studyJournal of neuro-oncology2026

Dose selection and clinical decision-making after Gamma Knife surgery for large brain metastases: implications for early identification of true progression.

Yuta Koketsu, Toshinori Hasegawa, Takenori Kato, Takehiro Naito, Akihiro Mizuno, Yuto Ando, Naofumi Kosaka, Ryuta Saito

Abstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in Journal of neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yuta KoketsuDepartment of Neurosurgery, Nagoya University School of Medicine, Nagoya, Aichi, Japan.
Toshinori HasegawaDepartment of Neurosurgery, Gamma Knife Center, Komaki City Hospital, Komaki, Aichi, Japan. h-toshi@komakihp.gr.jp.
Takenori KatoDepartment of Neurosurgery, Gamma Knife Center, Komaki City Hospital, Komaki, Aichi, Japan.
Takehiro NaitoDepartment of Neurosurgery, Gamma Knife Center, Komaki City Hospital, Komaki, Aichi, Japan.
Akihiro MizunoDepartment of Neurosurgery, Gamma Knife Center, Komaki City Hospital, Komaki, Aichi, Japan.
Yuto AndoDepartment of Neurosurgery, Gamma Knife Center, Komaki City Hospital, Komaki, Aichi, Japan.
Naofumi KosakaDepartment of Neurosurgery, Gamma Knife Center, Komaki City Hospital, Komaki, Aichi, Japan.
Ryuta SaitoDepartment of Neurosurgery, Nagoya University School of Medicine, Nagoya, Aichi, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo evaluate dose selection and post-treatment management after Gamma Knife surgery (GKS) for large brain metastases, with a focus on early identification of true progression.

methodsThis retrospective single-institution study included 143 patients with large brain metastases (tumor volume ≥ 4 cm

resultsMedian overall survival was 15.3 months. During follow-up, 47 lesions showed radiographic progression: 42 true progression, 4 pseudoprogression, and 1 intratumoral hemorrhage. The 6-, 12-, and 24-month cumulative incidences of true progression were 17.4%, 31.5%, and 33.1%, respectively. True progression did not differ by treatment modality or tumor volume. A marginal dose ≥ 57.6 Gy biologically effective dose (BED

conclusionA BED CLINICAL

trial registrationClinical trial number: not applicable.

Indexed as

Brain NeoplasmsClinical Decision-MakingRadiosurgeryAdultAgedAged, 80 and overDisease ProgressionFemaleFollow-Up StudiesHumansMaleMiddle AgedRetrospective StudiesSalvage TherapyGamma knifeHypofractionatedLarge brain metastasisSalvage therapyStereotactic radiosurgeryTumor control

Identifiers

PMID42832083

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.